AB Corporate Bond ETF Declares Monthly Dividend of $0.14 (NASDAQ:EYEG)

Posted by Lindsey Winhoffer on May 1st, 2026

AB Corporate Bond ETF (NASDAQ:EYEG – Get Free Report) declared a monthly dividend on Thursday, April 30th, NASDAQ Dividends reports. Shareholders of record on Friday, May 1st will be paid a dividend of 0.1404 per share by the specialty pharmaceutical company on Wednesday, May 6th. This represents a c) annualized dividend and a yield of 4.8%. The ex-dividend date is Friday, May 1st.

AB Corporate Bond ETF Trading Up 0.0%

Shares of AB Corporate Bond ETF stock traded up $0.01 on Friday, reaching $35.31. 108 shares of the company’s stock were exchanged, compared to its average volume of 204. The company has a market capitalization of $28.25 million, a P/E ratio of -21.02 and a beta of 0.23. AB Corporate Bond ETF has a 52 week low of $34.59 and a 52 week high of $36.63. The firm’s 50-day moving average is $35.47 and its two-hundred day moving average is $35.81. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.07 and a current ratio of 3.07.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Kestra Advisory Services LLC bought a new stake in AB Corporate Bond ETF in the fourth quarter valued at $34,000. Jane Street Group LLC bought a new position in shares of AB Corporate Bond ETF during the 2nd quarter worth about $232,000. Finally, Wealth Enhancement Advisory Services LLC boosted its position in shares of AB Corporate Bond ETF by 6.2% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 119,017 shares of the specialty pharmaceutical company’s stock worth $4,301,000 after purchasing an additional 6,988 shares in the last quarter. 64.16% of the stock is owned by institutional investors.

About AB Corporate Bond ETF

(Get Free Report)

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.